Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31214329 | 0.84 | KDM4E (0.50) | BCHEMAOBKDM4EALDH1A1IDO1 | |
| SCHEMBL2062788 | 0.84 | KDM4E (0.50) | BCHEMAOBKDM4EALDH1A1IDO1 | |
| SCHEMBL14117318 | 0.83 | KDM4E (0.56) | BCHEMAOBFFAR1FYNKDM4E | |
| SCHEMBL21116575 | 0.83 | IDO1 (0.50) | BCHEMAOBFFAR1KDM4EALDH1A1 | |
| SCHEMBL3978680 | 0.82 | KDM4E (0.52) | BCHEMAOBKDM4EALDH1A1 | |
| SCHEMBL1607526 | 0.82 | MAOB (0.48) | MAOBFFAR1KDM4EALDH1A1 | |
| SCHEMBL6489910 | 0.81 | MAOB (0.54) | MAOBFFAR1FYNTAAR1IDO1 | |
| SCHEMBL7323232 | 0.81 | MAOB (0.43) | BCHEMAOBFFAR1FYNKDM4E | |
| SCHEMBL1135279 | 0.81 | FYN (0.56) | MAOBFFAR1FYNKDM4EALDH1A1 | |
| SCHEMBL2438260 | 0.81 | MAOB (0.43) | MAOBFFAR1FYNKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640114-A | PD-L1 targeted molecular probe and preparation method and application thereof | 江苏省原子医学研究所 | 2023-08-25 | — | — | CN | claimed |
| CN-116640114-B | PD-L1 targeted molecular probe and preparation method and application thereof | 江苏省原子医学研究所 | 2024-05-14 | — | — | CN | disclosed |
| CN-116640114-A | PD-L1 targeted molecular probe and preparation method and application thereof | 江苏省原子医学研究所 | 2023-08-25 | — | — | CN | disclosed |
| US-10000443-B2 | Compositions and methods for glucose transport inhibition | OHIO UNIVERSITY (US) | 2018-06-19 | — | — | US | disclosed |
| US-20160137585-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160137585-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2016-05-19 | — | — | US | disclosed |
| US-9181162-B2 | Compositions and methods for glucose transport inhibition | OHIO UNIVERSITY (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181162-B2 | Compositions and methods for glucose transport inhibition | OHIO UNIVERSITY (US) | 2015-11-10 | — | — | US | disclosed |
| US-20120121536-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120121536-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | OHIO UNIVERSITY (US) | 2012-05-17 | — | — | US | disclosed |
| US-7037914-B2 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20050250824-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2005-11-10 | — | — | US | disclosed |
| CN-1213980-C | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2005-08-10 | — | — | CN | disclosed |
| CN-1616452-A | Vitamin d analogues | GALDERMA RES & DEV (FR) | 2005-05-18 | — | — | CN | disclosed |
| US-20030153579-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2003-08-14 | — | — | US | disclosed |
| CN-1423627-A | Vitamin D analogues | GALDERMA RES & DEV (FR) | 2003-06-11 | — | — | CN | disclosed |
| US-6506757-B1 | A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative, is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-01-14 | — | — | US | disclosed |
| EP-1067109-A1 | CARBOXYLIC ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
| CN-1268116-A | 3-amidinoaniline derivatives activated blood coagulation factor X inhibitors, and intermediates for producing both | KISSEI PHARMACEUTICAL (JP) | 2000-09-27 | — | — | CN | disclosed |
| EP-1020434-A1 | 3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS, AND INTERMEDIATES FOR PRODUCING BOTH | Kissei Pharmaceutical Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137585-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | SLC2A1, SLC2A4, SLC2A3 | BCHE 4803/4885MAOB 4311/4885FFAR1 169/4885 |
| US-20030153579-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | PPARA, PPARG, PPARD | BCHE 2411/4885MAOB 3666/4885FFAR1 9/4885 |
| US-20120121536-A1 | COMPOSITIONS AND METHODS FOR GLUCOSE TRANSPORT INHIBITION | SLC2A1, SLC2A4, SLC2A3 | BCHE 4803/4885MAOB 4311/4885FFAR1 169/4885 |
| US-10000443-B2 | Compositions and methods for glucose transport inhibition | SLC2A1, SLC2A4, SLC2A3 | BCHE 4803/4885MAOB 4311/4885FFAR1 169/4885 |
| US-20050250824-A1 | Carboxylic acid derivative and a pharmaceutical composition containing the derivative as active ingredient | PPARA, PPARG, PPARD | BCHE 1801/4885MAOB 3150/4885FFAR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.